| Patient | Leonard Nimoy |
|---|---|
| Date of birth | 1943-03-26 |
| Identifiers | MRN HR-ML017-SYN; SSN (made up) 000-17-6604 |
| Document date | 2026-11-01 |
| Author | Carla Benedetti, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for COPD and breathlessness walking any distance. Concerns: Breathlessness keeps him from walking any distance, and he uses a wheelchair at airports; Wants other smokers to quit before their lungs are damaged, and wants to keep working on his photography and writing. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two inhalations as needed for breathlessness (prescribed by his previous clinician; used once or twice most days before intake) | Two inhalations every 4 hours as needed, with a spacer | Respiratory tract route | 2025-09-15 | active | S |
| Tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations once daily | Two inhalations once each morning | Respiratory tract route | 2026-02-10 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Spirometry before and after albuterol 400 mcg: FEV1 1.18 L before and 1.26 L after bronchodilator (46 percent predicted), FVC 2.93 L, FEV1/FVC 0.43 after bronchodilator | 2026-02-10 to 2026-02-10 | completed | S |
| 12-lead ECG: sinus rhythm at 84 per minute, normal axis and intervals, no ischemic change or right heart strain | 2026-02-10 to 2026-02-10 | completed | S |
| Outpatient pulmonary rehabilitation, 24 supervised sessions over eight weeks (endurance and strength training, breathing techniques, inhaler and self-management education) | 2026-03-16 to 2026-05-08 | completed | S |
| Advance care planning conversation, about 25 minutes | 2026-10-06 to 2026-10-06 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-07 | High-dose influenza vaccine, 2025-2026 season | completed | S |
| 2019-04-16 | Recombinant zoster vaccine, two-dose series completed | completed | S |
| 2018-05-22 | Tdap vaccine | completed | S |
| 2026-05-12 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-10-06 | High-dose influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-06 | RSV vaccine, single dose | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| about 1984 | Former smoker who quit about thirty years before the index visit | D (CLM-0003) |
| January 2014 | Chronic obstructive pulmonary disease, disclosed publicly in late January, with breathlessness that keeps him from walking distances | D (CLM-0003, CLM-0004) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Breathlessness keeps him from walking any distance, and he uses a wheelchair at airports | active | S |
| Wants other smokers to quit before their lungs are damaged, and wants to keep working on his photography and writing | active | S |
Most recent measures: FEV1 --pre bronchodilation 1.18 on 2026-02-10; FEV1 --post bronchodilation 1.26 on 2026-02-10; FEV1 measured/predicted 46 on 2026-02-10; Forced vital capacity [Volume] Respiratory system --post bronchodilation 2.93 on 2026-02-10; FEV1/FVC --post bronchodilation 0.43 on 2026-02-10; Eosinophils [#/volume] in Blood by Automated count 0.18 on 2026-02-10; Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma 138 on 2026-02-10; Hemoglobin [Mass/volume] in Blood 14.6 on 2026-02-10; Creatinine [Mass/volume] in Serum or Plasma 0.98 on 2026-02-10; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-02-10; Six minute walk test 330 on 2026-05-12; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-06; Total score [Mini-Cog] 5 on 2026-10-06; Total score [AUDIT-C] 0 on 2026-10-06 [S]
Strengths and supports: Supports: spouse, adult children, long-time friends and colleagues; wants to use his experience to persuade smokers to quit [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic obstructive pulmonary disease, GOLD 3 (severe airflow limitation), group B, confirmed on spirometry; synthetic modern classification linked to his publicly disclosed COPD | active | confirmed | J44.9 | S — Synthetic modern spirometric classification; the COPD diagnosis itself is D from his own public disclosure. |
| Former smoker, quit about 30 years ago through a cessation program | active | confirmed | Z87.891 | S — Synthetic modern entry linked to his public account of quitting smoking. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-10 | FEV1 --pre bronchodilation | 1.18 | L | >=1.95 L | Low | S |
| 2026-02-10 | FEV1 --post bronchodilation | 1.26 | L | >=1.95 L | Low | S |
| 2026-02-10 | FEV1 measured/predicted | 46 | % | >=80% | Low | S |
| 2026-02-10 | Forced vital capacity [Volume] Respiratory system --post bronchodilation | 2.93 | L | >=2.75 L | Normal | S |
| 2026-02-10 | FEV1/FVC --post bronchodilation | 0.43 | {ratio} | GOLD fixed ratio 0.70; post-bronchodilator ratio below 0.70 confirms airflow obstruction | Low | S |
| 2026-02-10 | Eosinophils [#/volume] in Blood by Automated count | 0.18 | 10*3/uL | 0-0.5 10*3/uL | Normal | S |
| 2026-02-10 | Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma | 138 | mg/dL | 90-200 mg/dL | Normal | S |
| 2026-02-10 | Hemoglobin [Mass/volume] in Blood | 14.6 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-02-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-02-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-03-10 | Six minute walk test | 270 | m | Predicted about 480 m for his age, sex, height, and weight; lower limit about 380 m | Low | S |
| 2026-05-12 | Six minute walk test | 330 | m | Predicted about 480 m for his age, sex, height, and weight; lower limit about 380 m | Low | S |
| 2026-10-06 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-06 | Total score [Mini-Cog] | 5 | {score} | S | ||
| 2026-10-06 | Total score [AUDIT-C] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-10 | Body height | 185 | cm | S |
| 2026-02-10 | Body weight | 80 | kg | S |
| 2026-02-10 | Body mass index (BMI) [Ratio] | 23.4 | kg/m2 | S |
| 2026-02-10 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-02-10 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-02-10 | Heart rate | 84 | /min | S |
| 2026-02-10 | Respiratory rate | 20 | /min | S |
| 2026-02-10 | Body temperature | 36.7 | Cel | S |
| 2026-02-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 93 | % | S |
| 2026-03-10 | Body height | 185 | cm | S |
| 2026-03-10 | Body weight | 80.2 | kg | S |
| 2026-03-10 | Body mass index (BMI) [Ratio] | 23.4 | kg/m2 | S |
| 2026-03-10 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-03-10 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-03-10 | Heart rate | 82 | /min | S |
| 2026-03-10 | Respiratory rate | 18 | /min | S |
| 2026-03-10 | Body temperature | 36.6 | Cel | S |
| 2026-03-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 93 | % | S |
| 2026-05-12 | Body height | 185 | cm | S |
| 2026-05-12 | Body weight | 80.8 | kg | S |
| 2026-05-12 | Body mass index (BMI) [Ratio] | 23.6 | kg/m2 | S |
| 2026-05-12 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-05-12 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-05-12 | Heart rate | 78 | /min | S |
| 2026-05-12 | Respiratory rate | 18 | /min | S |
| 2026-05-12 | Body temperature | 36.7 | Cel | S |
| 2026-05-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 94 | % | S |
| 2026-08-11 | Body height | 185 | cm | S |
| 2026-08-11 | Body weight | 81 | kg | S |
| 2026-08-11 | Body mass index (BMI) [Ratio] | 23.7 | kg/m2 | S |
| 2026-08-11 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-08-11 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-08-11 | Heart rate | 76 | /min | S |
| 2026-08-11 | Respiratory rate | 18 | /min | S |
| 2026-08-11 | Body temperature | 36.6 | Cel | S |
| 2026-08-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 94 | % | S |
| 2026-10-06 | Body height | 185 | cm | S |
| 2026-10-06 | Body weight | 80.6 | kg | S |
| 2026-10-06 | Body mass index (BMI) [Ratio] | 23.6 | kg/m2 | S |
| 2026-10-06 | Systolic blood pressure | 130 | mm[Hg] | S |
| 2026-10-06 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-06 | Heart rate | 76 | /min | S |
| 2026-10-06 | Respiratory rate | 18 | /min | S |
| 2026-10-06 | Body temperature | 36.7 | Cel | S |
| 2026-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 94 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-02-10 | New patient visit for COPD and breathlessness walking any distance | finished | S |
| 2026-03-10 | Four-week COPD review after starting dual bronchodilator therapy, with pulmonology consultation | finished | S |
| 2026-05-12 | Three-month COPD review after pulmonary rehabilitation | finished | S |
| 2026-08-11 | Six-month COPD review | finished | S |
| 2026-10-06 | Subsequent annual wellness visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Start tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations each morning, keep albuterol as needed, and teach and check inhaler technique at every visit; no inhaled corticosteroid while there are no exacerbations and blood eosinophils are below 300 per microliter | completed | GL-GOLD-2025, GL-CMID-2026 | S |
| Pulmonology consultation to confirm the GOLD grade and group, review the inhaler choice and the place of an inhaled corticosteroid, assess oxygen need at rest and on exertion, interpret the alpha-1 antitrypsin result, and advise on pulmonary rehabilitation and lung cancer screening | completed | GL-GOLD-2025, GL-CMID-2026 | S |
| Outpatient pulmonary rehabilitation (mMRC 2 or more, GOLD 2 to 4), with a 6-minute walk test at entry and exit and a home exercise plan afterwards | completed | GL-ATS-PR-2023, GL-GOLD-2025, GL-CMID-2026 | S |
| At every visit: CAT, mMRC, exacerbations in the past 12 months, GOLD group, pulse oximetry, smoking status, BMI, and inhaler technique. Spirometry at diagnosis and at least yearly; alpha-1 antitrypsin once; blood eosinophils at baseline and before any change in inhaled corticosteroid; arterial blood gas only if resting saturation is 92 percent or less; long-term oxygen only for resting saturation of 88 percent or less confirmed twice at least three weeks apart; ECG and cardiovascular risk at baseline | completed | GL-CMID-2026, GL-GOLD-2025, GL-ATS-LTOT-2020 | S |
| Written COPD action plan: what an exacerbation looks like (more breathlessness, more or discolored sputum), when to use extra albuterol, and when to call the clinic the same day or go to emergency care | completed | GL-GOLD-2025, GL-CMID-2026 | S |
| Lung cancer screening reviewed and not offered: he quit smoking more than 15 years ago, so he does not meet the USPSTF criteria despite more than 20 pack-years | completed | GL-USPSTF-LUNG-2021, GL-CMID-2026 | S |
| Vaccines for COPD: yearly influenza (high dose at 65 and older), PCV20 once, RSV once at 75 and older, COVID-19 by CDC guidance, Tdap every ten years, and recombinant zoster | completed | GL-CMID-2026, GL-CDC-IMZ-2026 | S |
| Comorbidity and mood screening at intake and yearly (depression, anxiety, cardiovascular disease, osteoporosis, reflux, sleep, nutrition), and advance care planning at the wellness visit | completed | GL-GOLD-2025, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| CAT score at least 2 points lower by the three-month review | 2026-05-12 | completed | CAT fell from 22 to 15 | S |
| 6-minute walk distance at least 30 meters farther after pulmonary rehabilitation | 2026-05-12 | completed | 270 m at entry and 330 m at exit | S |
| No moderate or severe exacerbation over the six months after starting maintenance therapy | 2026-08-11 | completed | No exacerbation, oral corticosteroid course, antibiotic course, or emergency visit in six months | S |
| Correct soft mist inhaler technique and a daily maintenance dose | 2026-03-10 | completed | Correct technique on demonstration and no missed doses by dose counter at four weeks | S |